Oculis (NASDAQ:OCS) Reaches New 12-Month High – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $23.40 and last traded at $22.8690, with a volume of 67945 shares. The stock had previously closed at $22.03.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on OCS shares. Lifesci Capital assumed coverage on shares of Oculis in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 target price for the company. Stifel Nicolaus increased their price target on shares of Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Bank of America lowered their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oculis currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Stock Performance

The stock has a market capitalization of $1.23 billion, a P/E ratio of -9.34 and a beta of 0.31. The stock’s 50-day simple moving average is $19.84 and its 200 day simple moving average is $18.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last posted its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.23 million. Research analysts expect that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Aventura Private Wealth LLC acquired a new stake in shares of Oculis during the fourth quarter worth $80,000. Bosun Asset Management LLC bought a new position in Oculis during the second quarter worth about $378,000. Marshall Wace LLP acquired a new stake in Oculis in the 2nd quarter worth about $393,000. Geode Capital Management LLC boosted its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.